Talk:Supracompetitive pricing

Complaint

I disagree with this entire article.

Drugs companies (and I work well down the company chain in them) invest BILLIONS to develop a drug, their patent expires depending on the jurisdiction in seven or twelve years in which they have to recoup their money for their investment in the innovation. You can argue that yes or no but it is a supremely bad example and seems to me forced. Since in my life I have worked for drugs companies, defence (i.e. war) companies, and all kinds of other stuff I know my stuff here. It is HARD. If you don't want your nice drugs on you tabletop don't have them. So I think this is vaguely not NPOV (though it is so written) I think we need a less controversial example, at least to lead it as we develop tghe article-- then we can shove it in a section.

Nothing you have said is untrue, but I think biased.

SimonTrew (talk) 06:34, 12 February 2009 (UTC)

hello. im daisy, —Preceding unsigned comment added by 80.176.254.64 (talk) 10:55, 3 March 2009 (UTC)